Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | PRESIDENT AND COO | May 13, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UNITED THERAPEUTICS Corp
Report date May 13, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $217.50 · Expires 2033-03-15 | Direct | 0 |
Reported balance
After 2026-05-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-13 · Gift · Disposed 11,728 · Balance 0 F1: On March 13, 2026, the Reporting Person transferred stock options to a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $217.50 · Expires 2033-03-15 | Indirectby Trust | 99,720 |
Reported balance
After 2026-05-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-13 · Gift · Acquired 11,728 · Balance 99,720 F1: On March 13, 2026, the Reporting Person transferred stock options to a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. F2: Held in trusts beneficially owned by the Reporting Person, of which the Reporting Person or his family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 13, 2026, the Reporting Person transferred stock options to a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power.
F2: Held in trusts beneficially owned by the Reporting Person, of which the Reporting Person or his family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2026 Filed May 14, 2026 21:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GiftStock Option · Derivative | 11,728 | $0.00 Strike: $217.50 | $0.00 |
DisclosureSEC source: 0001673232-26-000014 · primarydocument.xml · derivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 99,720 Underlying: Common Stock · 11,728 shares Expires 2033-03-15 F1 · kind: On March 13, 2026, the Reporting Person transferred stock options to a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. F2 · ownership.nature: Held in trusts beneficially owned by the Reporting Person, of which the Reporting Person or his family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| May 13, 2026 Filed May 14, 2026 21:54 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GiftStock Option · Derivative | 11,728 | $0.00 Strike: $217.50 | $0.00 |
DisclosureSEC source: 0001673232-26-000014 · primarydocument.xml · derivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,728 shares Expires 2033-03-15 F1 · kind: On March 13, 2026, the Reporting Person transferred stock options to a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Units · Derivative | 15,592 | $0.00 | $0.00 |
DisclosureSEC source: 0001673232-26-000013 · primarydocument.xml · derivative · entry 7 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 0 Underlying: Common Stock · 15,592 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F5 · derivative.exercise_date: Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2023. F5 · derivative.expiration_date: Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2023. F2 · ownership.nature: Securities held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Units · Derivative | 17,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001673232-26-000013 · primarydocument.xml · derivative · entry 6 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 0 Underlying: Common Stock · 17,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F5 · derivative.exercise_date: Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2023. F5 · derivative.expiration_date: Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2023. F2 · ownership.nature: Securities held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Tax withholdingCommon Stock | 6,869 | $536.12 | $3,682,608.28 |
DisclosureSEC source: 0001673232-26-000013 · primarydocument.xml · nonDerivative · entry 4 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 19,046 F3 · shares: Represents the number of shares withheld by United Therapeutics for tax purposes, upon vesting of restricted stock units. F2 · ownership.nature: Securities held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Tax withholdingCommon Stock | 7,837 | $536.12 | $4,201,572.44 |
DisclosureSEC source: 0001673232-26-000013 · primarydocument.xml · nonDerivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 25,915 F3 · shares: Represents the number of shares withheld by United Therapeutics for tax purposes, upon vesting of restricted stock units. F2 · ownership.nature: Securities held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 15,592 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001673232-26-000013 · primarydocument.xml · nonDerivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 33,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F2 · ownership.nature: Securities held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 17,790 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001673232-26-000013 · primarydocument.xml · nonDerivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 17,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F2 · ownership.nature: Securities held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock · Derivative | 5,065 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001673232-26-000011 · primarydocument.xml · derivative · entry 7 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 Underlying: Common Stock · 5,065 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. The transactions reported on this Form 4 are the final transactions under this trading plan. F3 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock · Derivative | 9,375 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001673232-26-000011 · primarydocument.xml · derivative · entry 6 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 Underlying: Common Stock · 9,375 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. The transactions reported on this Form 4 are the final transactions under this trading plan. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 5,065 | $472.13 | $2,391,318.19 |
DisclosureSEC source: 0001673232-26-000011 · primarydocument.xml · nonDerivative · entry 4 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. The transactions reported on this Form 4 are the final transactions under this trading plan. F3 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 5,065 | $146.03 | $739,641.95 |
DisclosureSEC source: 0001673232-26-000011 · primarydocument.xml · nonDerivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 5,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. The transactions reported on this Form 4 are the final transactions under this trading plan. F3 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 9,375 | $472.13 | $4,426,181.25 |
DisclosureSEC source: 0001673232-26-000011 · primarydocument.xml · nonDerivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. The transactions reported on this Form 4 are the final transactions under this trading plan. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 9,375 | $117.76 | $1,104,000.00 |
DisclosureSEC source: 0001673232-26-000011 · primarydocument.xml · nonDerivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 9,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. The transactions reported on this Form 4 are the final transactions under this trading plan. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock · Derivative | 7,875 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001673232-26-000010 · primarydocument.xml · derivative · entry 7 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 5,065 Underlying: Common Stock · 7,875 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F3 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock · Derivative | 14,625 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001673232-26-000010 · primarydocument.xml · derivative · entry 6 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 9,375 Underlying: Common Stock · 14,625 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 7,875 | $480.75 | $3,785,934.60 |
DisclosureSEC source: 0001673232-26-000010 · primarydocument.xml · nonDerivative · entry 4 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F3 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,875 | $146.03 | $1,149,986.25 |
DisclosureSEC source: 0001673232-26-000010 · primarydocument.xml · nonDerivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 7,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F3 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 14,625 | $480.75 | $7,031,021.40 |
DisclosureSEC source: 0001673232-26-000010 · primarydocument.xml · nonDerivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 14,625 | $117.76 | $1,722,240.00 |
DisclosureSEC source: 0001673232-26-000010 · primarydocument.xml · nonDerivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 14,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock · Derivative | 7,875 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001673232-26-000009 · primarydocument.xml · derivative · entry 7 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 12,940 Underlying: Common Stock · 7,875 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F3 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock · Derivative | 14,625 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001673232-26-000009 · primarydocument.xml · derivative · entry 6 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 24,000 Underlying: Common Stock · 14,625 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 7,875 | $474.65 | $3,737,890.01 |
DisclosureSEC source: 0001673232-26-000009 · primarydocument.xml · nonDerivative · entry 4 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F3 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,875 | $146.03 | $1,149,986.25 |
DisclosureSEC source: 0001673232-26-000009 · primarydocument.xml · nonDerivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 7,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F3 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 14,625 | $474.65 | $6,941,795.74 |
DisclosureSEC source: 0001673232-26-000009 · primarydocument.xml · nonDerivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 14,625 | $117.76 | $1,722,240.00 |
DisclosureSEC source: 0001673232-26-000009 · primarydocument.xml · nonDerivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 14,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 7,875 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001673232-26-000008 · primarydocument.xml · derivative · entry 7 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 20,815 Underlying: Common Stock · 7,875 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F3 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 14,625 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001673232-26-000008 · primarydocument.xml · derivative · entry 6 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 38,625 Underlying: Common Stock · 14,625 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 7,875 | $470.95 | $3,708,750.15 |
DisclosureSEC source: 0001673232-26-000008 · primarydocument.xml · nonDerivative · entry 4 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F3 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,875 | $146.03 | $1,149,986.25 |
DisclosureSEC source: 0001673232-26-000008 · primarydocument.xml · nonDerivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 7,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F3 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 14,625 | $470.95 | $6,887,678.85 |
DisclosureSEC source: 0001673232-26-000008 · primarydocument.xml · nonDerivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 14,625 | $117.76 | $1,722,240.00 |
DisclosureSEC source: 0001673232-26-000008 · primarydocument.xml · nonDerivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 14,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 7,875 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · derivative · entry 23 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 28,690 Underlying: Common Stock · 7,875 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 14,625 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · derivative · entry 22 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 53,250 Underlying: Common Stock · 14,625 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F16 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 7,875 | $471.91 | $3,716,276.29 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · nonDerivative · entry 19 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,875 | $146.03 | $1,149,986.25 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · nonDerivative · entry 18 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 7,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 14,625 | $471.91 | $6,901,655.96 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · nonDerivative · entry 17 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F16 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 14,625 | $117.76 | $1,722,240.00 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · nonDerivative · entry 16 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 14,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F16 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 7,875 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · derivative · entry 21 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 36,565 Underlying: Common Stock · 7,875 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 14 | $470.76 | $6,590.57 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · nonDerivative · entry 15 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 84 | $470.37 | $39,511.08 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · nonDerivative · entry 14 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 14 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F15 · price: This transaction was executed in multiple trades at prices ranging from $469.73 to $470.70. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 451 | $469.18 | $211,600.09 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · nonDerivative · entry 13 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 98 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F14 · price: This transaction was executed in multiple trades at prices ranging from $468.73 to $469.65. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,573 | $468.12 | $736,346.94 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · nonDerivative · entry 12 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 549 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F13 · price: This transaction was executed in multiple trades at prices ranging from $467.73 to $468.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 321 | $467.09 | $149,936.28 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · nonDerivative · entry 11 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 2,122 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F12 · price: This transaction was executed in multiple trades at prices ranging from $466.73 to $467.70. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 568 | $466.06 | $264,723.84 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · nonDerivative · entry 10 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 2,443 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F11 · price: This transaction was executed in multiple trades at prices ranging from $465.62 to $466.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 966 | $465.11 | $449,295.78 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · nonDerivative · entry 9 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 3,011 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F10 · price: This transaction was executed in multiple trades at prices ranging from $464.62 to $465.615. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,225 | $464.06 | $568,468.48 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · nonDerivative · entry 8 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 3,977 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F9 · price: This transaction was executed in multiple trades at prices ranging from $463.61 to $464.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,322 | $463.26 | $612,430.25 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · nonDerivative · entry 7 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 5,202 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F8 · price: This transaction was executed in multiple trades at prices ranging from $462.61 to $463.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 271 | $461.12 | $124,963.06 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · nonDerivative · entry 6 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 6,524 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $460.56 to $461.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 268 | $459.86 | $123,243.74 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · nonDerivative · entry 5 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 6,795 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $459.55 to $460.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.